ArticleFrontiers in oncology2025
Prognostic significance of visceral pleural changes in stage IA lung adenocarcinoma: a retrospective study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Visceral pleural changes (VPC) is increasingly detected in early-stage lung adenocarcinoma, but its clinical and prognostic significance is unclear. This retrospective multicenter study aims to evaluate the influence of VPC on OS and DFS in patients with stage IA lung adenocarcinoma. Methods: Overall, 494 patients with stage IA lung adenocarcinoma from two centers were enrolled, including 202 VPC-positive (VPC+) and 292 VPC-negative (VPC-) patients. After 1:1 propensity score matching (PSM), 284 patients (142 per group) were analyzed. The Kaplan-Meier method was used to compare survival between groups, and Cox regression analysis identified independent prognostic factors for OS and DFS. Results: Kaplan-Meier analysis showed no significant OS difference between VPC+ and VPC- group (HR 0.67, 95% CI 0.31-1.47, P = 0.320). However, DFS was significantly better in VPC+ patients compared to VPC- patients (HR 0.51, 95% CI 0.27-0.94, P = 0.028). Specifically, 5-year OS was 96.5% in VPC+ vs. 95.8% in VPC- (P = 0.845), and 5-year DFS was 95.8% in VPC+ vs. 92.3% in VPC-(P = 0.259), with no significant differences. Median OS was 76.0 months before PSM and 76.0 months after PSM. For DFS, median time was 76.0 months before PSM and 76.0 months after PSM. Cox regression identified operative time as an independent OS prognostic factor (HR 1.01, 95% CI 1.00-1.11, P = 0.039), while VPC- (HR 0.40, 95% CI 0.19-0.83, P = 0.015) and pathological stage IA3 (HR 3.12, 95% CI 1.08-9.00, P = 0.035) were independent DFS prognostic factors. Conclusion: In patients with stage IA lung adenocarcinoma, VPC- is associated with worse DFS compared to VPC+, while no significant difference in OS was observed. Pathological stage were significant prognostic factors for DFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.